Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor  evolocumab: a prespecified secondary analysis of the FOURIER trial

LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much

one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between

progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the

FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).


Publicaciones Similares